Please wait while we load the requested 6-K report or click the link below:
https://last10k.com/sec-filings/report/1474835/000165495419001912/form6-k.htm
SEC Filings
IPCI Annual Reports
20-F Annual Report February 2019
20-F Annual Report March 2018
20-F Annual Report February 2017
20-F Annual Report March 2016
20-F Annual Report February 2015
20-F Annual Report February 2014
20-F Annual Report January 2013
20-F Annual Report May 2012
20-F Annual Report May 2011
20-F Annual Report June 2010
20-F Annual Report February 2019
20-F Annual Report March 2018
20-F Annual Report February 2017
20-F Annual Report March 2016
20-F Annual Report February 2015
20-F Annual Report February 2014
20-F Annual Report January 2013
20-F Annual Report May 2012
20-F Annual Report May 2011
20-F Annual Report June 2010
IPCI Corporate News
6-K Foreign Issuer Report March 2019
6-K Foreign Issuer Report March 2019
6-K Foreign Issuer Report March 2019
6-K Foreign Issuer Report February 2019
6-K Foreign Issuer Report February 2019
6-K Foreign Issuer Report February 2019
6-K Foreign Issuer Report January 2019
6-K Foreign Issuer Report January 2019
6-K Foreign Issuer Report
March 2019
6-K Foreign Issuer Report
March 2019
6-K Foreign Issuer Report
March 2019
6-K Foreign Issuer Report
February 2019
6-K Foreign Issuer Report
February 2019
6-K Foreign Issuer Report
February 2019
6-K Foreign Issuer Report
January 2019
6-K Foreign Issuer Report
January 2019
Last10K.com | 6-K Foreign Issuer Report Fri Feb 22 2019
View differences made from one to another to evaluate Intellipharmaceutics International Inc.'s financial trajectory
Compare this 6-K Foreign Issuer Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Intellipharmaceutics International Inc..
Assess how Intellipharmaceutics International Inc.'s management team is paid from their Annual Proxy
Intellipharmaceutics International Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:
- Voting Procedures
- Board Members
- Executive Team
- Salaries, Bonuses, Perks
- Peers / Competitors
SEC Filing Tools
Financial Statements, Disclosures and Schedules
Inside this 6-K Foreign Issuer Report
Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations And Comprehensive Loss
Consolidated Statements Of Shareholders' Equity (Deficiency)
Note 1 - Nature Of Operations
Note 1 - Nature Of Operations (Details Narrative)
Note 10 - Capital Stock
Note 10 - Capital Stock (Details Narrative)
Note 11 - Options
Note 11 - Options (Details 1)
Note 11 - Options (Details 2)
Note 11 - Options (Details 3)
Note 11 - Options (Details Narrative)
Note 11 - Options (Details)
Note 11 - Options (Tables)
Note 12 - Deferred Share Units
Note 12 - Deferred Share Units (Details Narrative)
Note 12 - Deferred Share Units (Details)
Note 12 - Deferred Share Units (Tables)
Note 13 - Restricted Share Units
Note 14 - Warrants
Note 14 - Warrants (Details 1)
Note 14 - Warrants (Details Narrative)
Note 14 - Warrants (Details)
Note 14 - Warrants (Tables)
Note 15 - Income Taxes
Note 15 - Income Taxes (Details 1)
Note 15 - Income Taxes (Details 2)
Note 15 - Income Taxes (Details Narrative)
Note 15 - Income Taxes (Details)
Note 15 - Income Taxes (Tables)
Note 16 - Contingencies
Note 17 - Financial Instruments
Note 17 - Financial Instruments (Details 1)
Note 17 - Financial Instruments (Details 2)
Note 17 - Financial Instruments (Details)
Note 17 - Financial Instruments (Tables)
Note 18 - Segmented Information
Note 18 - Segmented Information (Details)
Note 18 - Segmented Information (Tables)
Note 19 - Subsequent Event
Note 2 - Basis Of Presentation
Note 3 - Significant Accounting Policies
Note 3 - Significant Accounting Policies (Details Narrative)
Note 3 - Significant Accounting Policies (Details)
Note 3 - Significant Accounting Policies (Policies)
Note 3 - Significant Accounting Policies (Tables)
Note 4 - Accounts Receivable
Note 4 - Accounts Receivable (Details Narrative)
Note 5 - Property And Equipment
Note 5 - Property And Equipment (Details Narrative)
Note 5 - Property And Equipment (Details)
Note 5 - Property And Equipment (Tables)
Note 6 - Accrued Liabilities
Note 6 - Accrued Liabilities (Details)
Note 6 - Accrued Liabilities (Tables)
Note 7 - Due To Related Parties
Note 7 - Due To Related Parties (Details Narrative)
Note 7 - Due To Related Parties (Details)
Note 7 - Due To Related Parties (Tables)
Note 8 - Employee Costs Payable
Note 8 - Employee Costs Payable (Details Narrative)
Note 9 - Lease Obligations
Note 9 - Lease Obligations (Details)
Note 9 - Lease Obligations (Tables)
Material Contracts, Statements, Certifications & more
Intellipharmaceutics International Inc. provided additional information to their SEC Filing as exhibits
Ticker: IPCI
CIK: 1474835
Form Type: 6-K Foreign Issuer Report
Accession Number: 0001654954-19-001912
Submitted to the SEC: Fri Feb 22 2019 5:24:54 PM EST
Accepted by the SEC: Fri Feb 22 2019
Period: Friday, November 30, 2018
Industry: Pharmaceutical Preparations
External Resources:
Stock Quote
Social Media
Bookmark the Permalink: https://last10k.com/sec-filings/ipci/0001654954-19-001912.htm
SEC Filing Exhibit
PDF Download
Loading SEC Filing Exhibit...
Excel DownloadLoading SEC Filing Financial Summary...